Plectin-1 as a biomarker of malignant progression in intraductal papillary mucinous neoplasms a multicenter study

Maria Moris, David W. Dawson, Jennifer Jiang, Jason Lewis, Aziza Nassar, Kenneth K. Takeuchi, Anna R. Lay, Qihui Zhai, Timothy R. Donahue, Kimberly A. Kelly, Howard C. Crawford, Michael Wallace

Research output: Contribution to journalArticle

5 Scopus citations

Abstract

Objective: This study aimed to evaluate Plectin-1 expression as a biomarker of malignant risk for intraductal papillary mucinous neoplasms (IPMNs). Methods: Plectin-1 immunohistochemistry (IHC) was performed retrospectively on surgical (n = 71) and cytological (n = 33) specimens from Mayo Clinic Jacksonville and UCLA Medical Center, including IPMNs with low-grade dysplasia, high-grade dysplasia (HGD), or an associated invasive adenocarcinoma. Results: Plectin-1 expression was increased in invasive adenocarcinoma compared with adjacent in situ IPMN (P = 0.005), as well as the in situ HGD component of IPMNs with invasive cancer compared with HGD of IPMNs without invasive cancer (P = 0.02). Plectin IHC discriminated IPMNs with invasive adenocarcinoma from noninvasive IPMN (area under the curve [AUC] of 0.79, 75% sensitivity, and 85% specificity) but was insufficient for discriminating HGD IPMN from low-grade dysplasia IPMNs in surgical resections (AUC of 0.67, 56% sensitivity, and 64% specificity) or fine-needle aspiration specimens (AUC of 0.45). Conclusions: Although Plectin-1 IHC has insufficient accuracy to be used as a definitive biomarker for malignant risk in the evaluation of IPMN biopsy or cytological specimens, increased Plectin-1 expression observed in both invasive cancer and in situ HGD of malignant IPMNs suggests that it might be successfully leveraged as a cyst fluid biomarker or molecular imaging target.

Original languageEnglish (US)
Pages (from-to)1353-1358
Number of pages6
JournalPancreas
Volume45
Issue number9
DOIs
StatePublished - Sep 15 2016

Keywords

  • Biomarker
  • Branch duct IPMN
  • Immunohistochemistry
  • Intraductal papillary mucinous neoplasm (IPMN)
  • Malignant progression
  • Pancreatic adenocarcinoma
  • Plectin-1

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Hepatology
  • Endocrinology

Fingerprint Dive into the research topics of 'Plectin-1 as a biomarker of malignant progression in intraductal papillary mucinous neoplasms a multicenter study'. Together they form a unique fingerprint.

  • Cite this

    Moris, M., Dawson, D. W., Jiang, J., Lewis, J., Nassar, A., Takeuchi, K. K., Lay, A. R., Zhai, Q., Donahue, T. R., Kelly, K. A., Crawford, H. C., & Wallace, M. (2016). Plectin-1 as a biomarker of malignant progression in intraductal papillary mucinous neoplasms a multicenter study. Pancreas, 45(9), 1353-1358. https://doi.org/10.1097/MPA.0000000000000652